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Beyond current research practice: methodological considerations in MS rehabilitation 
research (Is designing the perfect rehabilitation trial the Holy Grail or a Gordian knot?) 
 
Rehabilitation is an essential aspect of symptomatic and supportive treatment for people with 
multiple sclerosis (MS). MS rehabilitation research has grown considerably, but the volume 
of robust evidence to guide effective clinical practice in the form of high quality randomised 
controlled trials (RCTs) is low1. Such robust research evidence is important because it is a 
key driver for optimising patient outcomes and service delivery2, and influencing health 
policy decision making.  
 
This discussion paper explores some of the challenges of undertaking robust clinical trials 
within this field. We acknowledge the importance of using a variety of research methods to 
fully understand whether and how rehabilitation interventions work, but focus on RCTs since 
they are arguably regarded as a superior research design to determine whether a treatment is 
beneficial3. However, RCTs have largely been modelled on pharmacological trials where the 
precise dose of the intervention, double blind procedures, and safety reporting mechanisms 
can be strictly adhered to. Such issues become much more complex in rehabilitation trials. 
Therefore, additional guidelines for conducting and reporting non-pharmacological trials 
have been published4. Despite these advances, reporting has not yet significantly improved 5 
and specific challenges persist.   
 
We describe some key methodological issues faced in rehabilitation trials, and draw upon 
examples from both within and outside the MS field, where these dilemmas have been (at 
least partially) tackled. We make some suggestions as to how future research can be 
scientifically robust whilst remaining relevant and “fit for purpose” in generating new 
knowledge, which can meaningfully shape rehabilitation practice and improve patient 
outcomes.      
 
Trial designs – efficacy vs. effectiveness trials 
All RCT designs share some common features (e.g., randomisation), but they also differ 
based on the general aims of the RCT. Efficacy (or explanatory) trials, which are often highly 
controlled, aim to answer whether an intervention produces benefits for patients under ideal 
(often laboratory) conditions, and are typically used to demonstrate ‘proof-of-principle’ for 
newer interventions. An example of an efficacy rehabilitation trial is Dalgas et al.5. 
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Effectiveness (or pragmatic) trials aim to answer whether an intervention produces benefits 
for patients under usual clinical (real-world) conditions, to determine whether the 
intervention translates to clinical practice, and how and with whom the intervention could be 
used6. An example of an effectiveness rehabilitation trial is Boesen et al.7. Despite this 
distinction, efficacy and effectiveness trials should be seen as two ends of a continuum8. Both 
serve different functions9, can be equally robust, and are required. The key, at the design 
stage, is determining what kind of trial is needed, with clarity and transparency about the 
research questions being posed. Based on this distinction, trials vary in relation to 
Participants, Intervention, Control, and Outcomes (PICO).  
 
1. Participants  
(i) Selection 
Several factors influence participant recruitment, including whether the study is an efficacy 
trial (requiring a homogenous sample meeting specific entry criteria) or an effectiveness trial 
(requiring a more heterogeneous sample to enable generalisability). Trials are sometimes 
criticised for not recruiting participants akin to patients seen in clinical practice (with 
multiple comorbidities and illness profiles, from different backgrounds), or are drawn from 
specific services or geographical locations with regional idiosyncrasies, thereby questioning 
the generalisability of the findings10. This criticism can be addressed if trialists specify the 
trial type. Also important is distinguishing between the proportion of participants eligible for 
the intervention and those unable to participate in the research study (exclusions such as 
reduced capacity for consent, enrolment on another trial), to provide a clearer indication of 
how many people would benefit from the intervention if it were part of routine practice.  
 
Participants should be recruited based on the goal of the rehabilitation intervention. Some MS 
rehabilitation trials have not done this. For instance, a Cochrane review of exercise 
interventions for fatigue in MS concluded that most trials did not explicitly include people 
who experienced fatigue11. This could have affected the overall ‘effectiveness’ of the 
intervention.  
 
Often neglected in terms of participant selection is a participant’s readiness for the 
intervention or behavioural change. This is particularly important in rehabilitation trials 
where participants need to actively engage in the treatment to derive benefit. Using strategies 
such as motivational interviewing has demonstrated improvement in participant engagement, 
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therapy adherence, outcomes, and patient-provider relationships12. Consideration of this 
variable as an inclusion criterion or moderator may enhance understanding about differential 
treatment effects.  
 
As per CONSORT guidelines for non-pharmacological trials13, a table showing baseline 
demographic and clinical characteristics for each group should be presented. Related to this, 
as recommended by an international workshop addressing comorbidity in clinical trial design 
and conduct14, trialists should present comorbidity status of participants, and where possible, 
evaluate treatment response, tolerability, and safety based on comorbidity. Furthermore, 
when applicable, a description of care providers (case volume, qualification, expertise, etc.) 
and rehabilitation context should also be documented. 
 
(ii) Sample size 
In RCTs a sample with the specific attribute of interest is selected and studied, and the 
findings “extrapolated”15. Having a small study risks making a Type II error. Indeed, most 
trials with ‘negative results’ are with small samples, under-powered to detect significant 
differences between groups16. Having ‘too many’ people also poses ethical and resource 
issues15. Therefore, an a priori sample size calculation is required to identify the numbers 
needed. However, we still find MS rehabilitation trials where sample size calculations are not 
reported. 
 
Publication bias (i.e., only trials with positive findings being reported17 in meta-analysis are 
more likely to affect small studies18. Given that most MS rehabilitation trials are ‘small’, it is 
concerning that many of the systematic reviews (including several Cochrane Reviews) have 
not formally assessed publication bias, despite evidence that publication bias exists in some 
MS rehabilitation trials11, 19. Assessing this will enable a fuller understanding of the state of 
the science.  
 
There are, however, complexities in determining sample size in trials of ‘complex 
interventions’, such as rehabilitation, because determining a clinically meaningful difference 
on outcome measures can be difficult (see below).   
 
2. Intervention  
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Rehabilitation is a “process of assessment, treatment and management by which the 
individual (and their family/carers) are supported to achieve their maximum potential for 
physical, cognitive, social and psychological function, participation in society and quality of 
living” (p2,20). It is often provided by different healthcare professionals, based on specific 
needs (such as neuropsychological rehabilitation), or specific symptoms (such as mobility 
problems), and in a holistic fashion by a coordinated inter-disciplinary team21, with access to 
several specialist health professions22.  
  
(i) Dose of treatment 
Unlike pharmacological interventions, within much of MS rehabilitation research the optimal 
‘dose’ of the intervention, and when to deliver this (e.g., time post-relapse) is yet to be 
established. The reasons for this are manifold. In some areas (e.g., cognitive rehabilitation), 
few large, well-conducted trials are available, so dose-response analyses have not been 
performed. Where rehabilitation packages containing several ‘modules’ are evaluated, 
oftentimes, it is the whole package that is evaluated, so the relative effect of each module is 
unknown. Also, the complex nature of the intervention means that combined effects of a 
combination of modules may be greater than the sum of the parts. Finally, there is a 
recognition, in other areas of neurology, that higher doses of rehabilitation training do not 
always provide better results23. This may also be the case in MS, for instance when 
impairments (such as fatigue or weakness) and disabilities are very severe.  Rule-based dose-
finding trial designs are one way of tackling this issue. More commonly used in 
pharmaceutical research, they have recently been undertaken in stroke rehabilitation to 
determine the optimal dose for specific intervention prior to undertaking an efficacy study24. 
These studies utilise an adaptive design approach to enable dose escalation/de-escalation 
according to pre-set rules and a mathematical sequence, thereby allowing exploration of the 
dose-response relationship, whilst minimising sample size and maintaining participant safety.  
 
(ii) Description of the intervention 
Describing and characterising the “black box” of rehabilitation is important to enable 
replication of studies and implementation of interventions based on what was trialled. 
Checklists and guidelines like the Template for Intervention Description and Replication 
(TIDieR)25 can help researchers report interventions more thoroughly, however this is not yet 
commonplace in MS rehabilitation research. For instance, in a systematic review of trials 
evaluating cognitive rehabilitation (k=52), the reporting of key aspects of the intervention 
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was judged to be poor, particularly in relation to content of the intervention, delivery mode, 
and proposed mechanism of action26.   
 
(iii) Active ingredients  
What constitutes the active ingredients of rehabilitation, which typically uses a multi-
component biopsychosocial model27, 28, is difficult to determine. For instance, many 
interventions incorporate several settings, healthcare providers and treatment techniques 
based on the premise that a successful outcome is a result of this cross-fertilisation of inputs. 
Further, the core principle of many rehabilitation interventions is to actively engage 
individuals in change processes such as learning, practicing, and developing skills to enhance 
coping and adaptation across diverse outcomes.  
 
Psychotherapy research demonstrates that where different therapies produce similar 
outcomes, this is because of a set of ‘common factors’, with ‘therapeutic alliance’ between 
the patient and therapist being most relevant29. MS rehabilitation research has rarely 
evaluated such common factors, however, there is some consensus regarding what the ‘key’ 
(if not ‘active’) ingredients, and mode of delivery are in some rehabilitation interventions 
(e.g., falls30, 31, fatigue32-34).  
 
Understanding the mechanism of action, its target, and desired effect is also important in 
defining the active ingredients. Advances in neuroscience, such as functional imaging 
techniques that enable investigation of neuroplastic adaptations35, provide important insights 
into this. But equally, easy-to-collect patient-reported outcomes can improve our 
understanding of underlying mechanisms36. While these may not be a trial’s main outcomes, 
embedding this work within clinical trials provides opportunities to advance knowledge of 
how treatments work, and to develop new recovery-oriented strategies in MS. For instance, 
video recordings of therapists delivering the trial intervention can enable us to determine the 
degree to which therapist competence is associated with patient outcomes37, or mixed 
methods designs collecting patient and therapist perspectives can improve our understanding 
of the perceived effects and experiences of interventions38. 
 
(iv) Fidelity of intervention delivery 
Given the complex nature of most rehabilitation interventions, in the context of a trial, it is 
vital for reliability and validity of the findings that the intervention is delivered as intended, 
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consistently across participants and sites, and any deviations from the planned intervention 
recorded. While some MS trials describe intervention fidelity39, 40, this is not yet the norm, 
despite guidelines available on treatment fidelity in health behaviour change studies41, which 
can be adapted for MS rehabilitation trials. This said, assessing fidelity in complex 
interventions is challenging, because it not only requires an examination of what was 
delivered (content), but also how the intervention was delivered (process). Much of the 
literature around fidelity assessments in trials tends to focus on ‘implementation fidelity’ (i.e., 
how the intervention was delivered, dose received, etc.) and ‘theoretical fidelity’ (i.e., how 
the intervention delivered matched the theoretical underpinning of the intervention)42. 
However, these still neglect the quality of the intervention delivery and the quality of the 
therapeutic relationship. This, however, is rarely assessed in MS rehabilitation trials.  
 
(v) Targeting of interventions  
Related to the notion of ‘person-centredness’, a criticism levelled against RCTs in 
rehabilitation is that oftentimes the intervention is not sufficiently individualised. This is 
particularly challenging with group-based interventions, although some attempts have been 
made to personalise interventions. For instance, in a memory rehabilitation RCT, baseline 
memory assessment scores were used to highlight which memory strategies might be more 
useful than others, and homework exercises enabled participants to test memory strategies 
within their home settings to determine what adaptations needed to be made to the 
strategies43. Similar approaches have been used in MS RCTs of fatigue36 and falls44 
interventions.  
 
(vi) Treatment adherence  
The success of a treatment is partly dependent on patients’ adherence. Where patients are 
required to actively participate over a long period, there is often considerable variation in 
adherence45. While there are some good examples of MS rehabilitation trials that report 
adherence46, this appears less well described in some domains (such as memory/cognition47). 
It would be beneficial for trials to report the minimum number of sessions (or other marker of 
dose) required to demonstrate effect, and the actual number of sessions that participants 
engage in. The risk of not specifying the actual ‘amount’ of intervention participants received 
is that where trials show ‘no intervention effect’, it is difficult to disentangle whether the 
treatment was ineffective or whether people did not engage in the required dose of the 
intervention.  
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Despite some challenges in their use48, wearable technologies (sensors and/or software 
applications on watches, smartphones, shoes, etc.) can be embedded within RCTs, and can 
provide an opportunity to objectively capture adherence or behavioural changes outside 
clinical settings, within the ‘real world’.  
 
3. Control groups 
There are several approaches available when deciding which control condition is most 
appropriate49. Whilst one option is to withhold active treatment, ethical issues need to be 
considered, such as the nature of the target problem, the state of science with regard to the 
effectiveness of existing treatments, and lack of acceptability to participants – which might 
affect recruitment, retention and data integrity. An alternative is the wait-list control design, 
which has been used in several RCTs of multi-disciplinary packages of rehabilitation50 and 
single component interventions such as tele-rehabilitation51, 52. This approach can control for 
the effects of time, guaranteeing eventual intervention, reflecting the realities of clinical 
waiting lists, and being more acceptable to potential participants. However, there is the risk 
that simply knowing that they will eventually receive the intervention may change the nature 
of the controls, and may not represent the experience or response to those who do not receive 
an intervention. Controls that involve comparison to usual care are more commonly used in 
rehabilitation RCTs, and whilst useful for examining the added value of an intervention, they 
are complicated by the fact that usual care is often highly variable and may require large 
samples to achieve adequate statistical power.  
 
Active controls, wherein active treatments are compared to the test intervention (e.g., 
equivalence trials), are challenging in terms of defining the active ingredients, and being clear 
about what elements are most essential to control for (e.g., dose, attention, etc.) in 
behavioural-based ‘complex’ interventions, with multiple ‘active ingredients’ that may be 
difficult to characterise. Nevertheless, this has been achieved in some rehabilitation trials of 
exercise53, 54 and cognition55, although these trials have investigated single interventions that 
typically have not incorporated a behavioural approach. Finally, some trials have used 
attention placebo controls, wherein control participants receive an intervention that is 
plausible, mimicking the amount of time and attention received by the treatment group, but is 
thought not to have a specific effect on the outcomes of interest. Arguably, this can be 
ethically defensible when no effective treatment has proven to exist, which is commonplace 
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for MS rehabilitation, and when participants know what to expect in each treatment arm. This 
is a challenge for behavioural-based interventions since it requires double blinding, which 
often cannot be accomplished in the MS rehabilitation field. Studies in MS rehabilitation 
have achieved this, but have involved “passive” interventions not requiring active 
engagement by the participants to affect target outcomes56, 57. Others have attempted to 
include attention placebo groups, where the facilitators do not present the presumed active 
ingredients in the sessions, but do not (and cannot) prevent participants from discussing the 
issues they struggle with (e.g., memory55).  
 
4. Outcomes  
(i) Choice of outcomes  
The International Classification of Functioning, Disability and Health (ICF) is the World 
Health Organisation’s “framework for measuring health and disability at both individual and 
population levels”58 and is consistent with the aims of rehabilitation. Outcomes can be at an 
impairment, activity, or participation level, but we cannot assume that improvements at 
impairment level will generalise to reductions in activity limitations and participation 
restrictions. There are however, examples where this is the case, for example strengthening of 
lower limbs has shown to improve mobility in people with MS59. Whether or not translation 
from impairment to activity limitations/participation is seen, should be explicitly and 
systematically reported so that clear conclusions can be drawn.   
 
It is important to consider health economic outcomes, particularly in pragmatic trials where 
policy decisions need to be based on both clinical and cost-effectiveness data. MS 
rehabilitation trials have begun addressing this43, 44, 60-63. Quality of life (QoL) is sometimes 
considered a desirable ‘general’ outcome of rehabilitation trials. While this is laudable, there 
are challenges in using such an outcome. As a primary outcome for specific types of 
rehabilitation (e.g., cognitive rehabilitation), improvements may not be observed on QoL 
measures as a consequence of the intervention because QoL is often a composite construct 
(e.g., measures may include items related to fatigue, pain, social and physical function), 
whereas the intervention may only be able to change one aspect (e.g., cognition or social 
function). Baumstarck et al.64 provide a good summary of some of the issues in assessing 
QoL in people with MS. Similar issues may arise when using generic activities of daily living 
scales or participation scales wherein a total score is derived from multiple items. In such 
instances, subset or domain-specific scores may be more appropriate as a primary outcome.  
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Capturing adverse events in complex intervention trials is challenging, because the chance of 
detecting them may differ between treatment arms. Furthermore, in some rehabilitation trials, 
the primary outcome may also be considered as an adverse event (e.g., falls frequency in falls 
prevention interventions65, 66. Despite these challenges, and although many rehabilitation 
trials are considered ‘low risk’, it is important to consider the potential adverse events, how 
these will be assessed, monitored, reported, and addressed60, 61, 67.  
 
(ii) Number of outcomes 
It is tempting to use a large number of outcomes to capture any potential effect in 
rehabilitation trials. This has the disadvantage of increasing the risk of false positive findings. 
Nonetheless, in a complex intervention trial, it may be appropriate to have different types of 
outcomes that relate to the key clinical or economic variables. In addition, mechanistic 
measures may be useful to unpack why an intervention worked (or not).  
 
(iii) Defining a primary outcome 
Scientific rigor in RCTs rightly demands that the primary and secondary outcomes are 
defined beforehand, because the trial is powered based on finding a clinically relevant effect 
of the intervention on the primary outcome. All outcomes need to be described as primary or 
secondary (in the protocol or trial registry), and should be analysed and reported, in line with 
CONSORT guidelines13. Unfortunately, reviews find that not all MS rehabilitation trials do 
this11, 19. Selecting and reporting on a limited number of pre-specified (primary) outcomes, 
with a clear rationale for selecting them, limits the risk of bias and is an important 
consideration to building a solid evidence base for rehabilitation interventions. Core Outcome 
Sets for rehabilitation trials in MS have been recommended for various types of rehabilitation 
(e.g., exercise interventions68), and the recommendations of the American Physical Therapy 
Association's Multiple Sclerosis Outcome Measures Task Force69 can be used to guide 
trialists in selecting outcome measures. 
 
(iv) Timing of outcomes 
The time point of primary concern should be specified in advance of the analysis. Because it 
is likely that the best outcome is seen immediately after the intervention, outcomes assessed 
at this time-point can be useful to determine effectiveness of the intervention. However, this 
leaves uncertainty as to the long-term benefits. Treatment effects can gradually wear off34 or, 
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particularly with regard to impact on activities and participation, can take longer to 
establish70. The selection of one time point (either long- or short-term) limits insight into 
what happens during the rehabilitation process, and restricts the use of powerful longitudinal 
analysis techniques that can help to understand the course of treatment effects. The time point 
of primary concern, however, should be specified in advance of the analysis. 
 
(v) Defining a clinically important/meaningful difference 
Labelling the result of a trial as “positive” or “negative” is often inappropriately based on 
whether or not statistical significance is achieved for the primary outcome71-73. It is more 
important to show that a pre-specified difference in scores between groups is clinically 
relevant74. Nevertheless, sound evidence on minimal clinically important differences (MCID) 
of outcomes is often unavailable, barring some good exceptions43, 75-78.  
 
(vi) Statistical analysis  
Several MS rehabilitation trials conduct significance testing comparing baseline with follow-
up outcome scores (within group changes) rather than comparing randomised groups directly 
(between-group differences), which can be highly misleading79. Analyses plans should be 
decided before the data are locked and deviations from this plan should be specified in the 
publication of trial results, with some arguing that pre-specified statistical analysis plans 
should be published prospectively80.  
 
A summary of these issues and suggestions is provided in Table 1. 
 
[Insert Table 1 here] 
 
Conclusions and future directions  
 
We have made much progress in undertaking, conducting, and reporting RCTs in MS 
rehabilitation research, but there is some way to go yet.  
 
We believe we can improve the design, conduct, and reporting of trials by following 
internationally-accepted RCT guidelines (see www.equator-network.org), and by developing 
a critical mass of MS rehabilitation researchers, perhaps by extending and intensifying 
cooperation within organisations such as Rehabilitation in MS (www.eurims.org), to 
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undertake high quality rehabilitation trials. We may need to extend our collaborations with 
“critical friends” outside of the area of MS to facilitate inter- and cross-disciplinary ways of 
addressing shared methodological dilemmas. One such group might be the newly formed 
Cochrane Rehabilitation Field (www.rehabilitation.cochrane.org), which may be a vehicle to 
improve research methods (for trials and syntheses), publicise results, and drive forward 
evidence-based clinical care.  
 
The ICF is an excellent framework to map rehabilitation trial outcomes. More, however, can 
be made in relation to the ‘personal’ and ‘environmental’ aspects of the ICF, perhaps as 
understanding prognostic factors that relate to outcome, or in relation to clinical 
implementation of positive trials.  
 
We also believe work is needed to ensure that journal editors and reviewers judge 
rehabilitation trials in the light of the specific challenges posed in designing these trials, and 
view the merits of the trials based on internationally-recognised RCT guidelines for complex 
intervention trials, rather than compare them with pharmacological trials. We need research 
that covers the full cycle of the Medical Research Council’s framework for the development 
and evaluation of complex interventions81 - from developing and modelling interventions, to 
feasibility and pilot testing, to pragmatic trials and implementation studies. Most MS 
rehabilitation trials have focussed on the earlier parts of the cycle, and there is a need for 
more pragmatic trials evaluating clinical and cost-effectiveness, for translation of findings 
from research to clinical practice. ‘Null’ or ‘negative’ results should be published. Some 
journals, including MSJ, accept “short reports on null or negative results”. This is important 
for the advancement of science. We would, however, suggest that such trials should not be 
limited to “short” reports, and indeed, may be worthy of longer reports given that such results 
need to be expanded further and the pathways for future research in the field should be 
clearly stated. Such papers have spurred great developments in the field82.  
 
We need to continue to critique, challenge and develop RCT designs. Because most 
rehabilitation interventions are complex interventions, outcomes-focussed trials only address 
whether an intervention is effective or not and do not offer answers to more nuanced 
questions: “When and for what kind of patient is this intervention effective?” 
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It is clear that undertaking scientifically rigorous research that is clinically meaningful is a 
complex problem, but we believe it is not unsolvable. Just as Alexander the Great 
disentangled the Gordian knot, so too can clinicians, researchers and people with MS work 
together to systematically conquer the methodological conundrums that currently challenge 
us.     
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